Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02026609 · ClinicalTrials.gov registry record
Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 3
- Enrollment target
NCT02026609: Clinical Trial study, sponsored by University of Arkansas.
NCT02026609 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02026609 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge (OGC) and psychometric tests have been used to assess the risk for HE, but never in patients undergoing TIPS. Severe muscle loss may also predispose patients to HE. The aim of the present study is to assess if both the OGC and psychometric tests can accurately predict the development of overt HE after TIPS. Patients will be studied before TIPS and followed after TIPS for the development of HE. The role of muscle loss in favoring HE, as well as is possible reversibility after TIPS will also be investigated.
Primary Outcome
Classified according to West Haven criteria.
Interventions
- OTHER Oral glutamine challenge
- OTHER Psychometric Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-01-27 |
Why NCT02026609 stopped before completion
NCT02026609 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Oral glutamine challenge is the first listed.
NCT02026609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02026609 about?
NCT02026609 is a clinical study titled "Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)". Transjugular intrahepatic portosystemic shunt (TIPS) is the first-line therapy for patients with cirrhosis and refractory ascites. However, mental changes known as hepatic encephalopathy (HE) frequently occur after TIPS. There is no effective method to predict HE after TIPS. Oral glutamine challenge...
What is the current status of trial NCT02026609?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2013-05. Estimated completion is 2015-01-27.
What interventions are being tested in trial NCT02026609?
The interventions under investigation include: Oral glutamine challenge (OTHER), Psychometric Tests (OTHER).
Who is sponsoring clinical trial NCT02026609?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia